1. Home
  2. SCLX vs ANTX Comparison

SCLX vs ANTX Comparison

Compare SCLX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • ANTX
  • Stock Information
  • Founded
  • SCLX 2011
  • ANTX 2017
  • Country
  • SCLX United States
  • ANTX United States
  • Employees
  • SCLX N/A
  • ANTX N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • ANTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCLX Health Care
  • ANTX Health Care
  • Exchange
  • SCLX Nasdaq
  • ANTX Nasdaq
  • Market Cap
  • SCLX 35.7M
  • ANTX 31.4M
  • IPO Year
  • SCLX N/A
  • ANTX 2022
  • Fundamental
  • Price
  • SCLX $24.96
  • ANTX $1.29
  • Analyst Decision
  • SCLX Strong Buy
  • ANTX Buy
  • Analyst Count
  • SCLX 3
  • ANTX 2
  • Target Price
  • SCLX $367.50
  • ANTX $2.00
  • AVG Volume (30 Days)
  • SCLX 205.7K
  • ANTX 80.6K
  • Earning Date
  • SCLX 08-13-2025
  • ANTX 11-12-2025
  • Dividend Yield
  • SCLX N/A
  • ANTX N/A
  • EPS Growth
  • SCLX N/A
  • ANTX N/A
  • EPS
  • SCLX N/A
  • ANTX N/A
  • Revenue
  • SCLX $44,236,000.00
  • ANTX N/A
  • Revenue This Year
  • SCLX $89.26
  • ANTX N/A
  • Revenue Next Year
  • SCLX $203.95
  • ANTX N/A
  • P/E Ratio
  • SCLX N/A
  • ANTX N/A
  • Revenue Growth
  • SCLX N/A
  • ANTX N/A
  • 52 Week Low
  • SCLX $3.60
  • ANTX $0.98
  • 52 Week High
  • SCLX $39.90
  • ANTX $1.68
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 64.44
  • ANTX 62.56
  • Support Level
  • SCLX $22.45
  • ANTX $1.22
  • Resistance Level
  • SCLX $27.58
  • ANTX $1.33
  • Average True Range (ATR)
  • SCLX 2.32
  • ANTX 0.08
  • MACD
  • SCLX 0.09
  • ANTX 0.01
  • Stochastic Oscillator
  • SCLX 74.71
  • ANTX 85.71

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Share on Social Networks: